Related Experiment Video
Updated: Jan 30, 2026

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
Published on: February 19, 2021
Rebound of medication abortion in Texas following updated mifepristone label
Sarah E Baum1, Kari White2, Kristine Hopkins3
1Texas Policy Evaluation Project, Austin, TX; Ibis Reproductive Health, Oakland, CA.
Background:
In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label.
Methods:
Using data collected directly from Texas abortion facilities, we evaluated changes in the provision and use of medication abortion during three 6-month time periods corresponding to the policy changes: before HB 2, after HB 2 and after the label change.
Results:
Medication abortion constituted 28% of all abortions before HB 2, 10% after implementation of the restrictions and 33% after the label change.
Conclusions:
Use of medication abortion in Texas rebounded after the FDA label change.
Related Concept Videos
Inhaled Medications
Endocarditis III: Medical Management
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Heart Failure V: Medical Management
Mitral Stenosis III: Medical Management

